- In February 2025, Boryung launched Rebetrix Capsules a combination of aspirin and rabeprazole, designed to reduce gastrointestinal bleeding risks associated with aspirin use through the protective effects of rabeprazole
- In January 2025, Preeclampsia Foundation in partnership with Patients & Purpose introduced GAP—SPIRIN, an evidence-based education campaign promoting the use of low-dose aspirin to prevent preeclampsia and address maternal health disparities
- In November 2023, Janssen presented new data at the American Heart Association's (AHA) 2023 Scientific Sessions, highlighting that combining XARELTO with aspirin can help reduce critical cardiovascular and adverse limb events
- In March 2023, the FDA approved Plx Pharma Inc.’S Sndas for Vazalore 325 mg and 81 mg, a liquid-filled aspirin capsule intended for patients with vascular disease and diabetes
- In July 2021, Dr. Reddy's Laboratories Ltd launched ROZAT GOLD in India, a fixed-dose combination (FDC) drug containing aspirin, rosuvastatin, and clopidogrel, designed for high-risk cardiovascular conditions such as chronic coronary artery disease and acute coronary syndrome
